MEDISCA
26.5.2022 18:19:08 CEST | Business Wire | Press release
On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP , by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio).
“Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca.
“After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, channels, and patients across the globe. A need we will now meet through our partnership with SUANFARMA.”
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price.
“The quality standards set, transparency created, and commitment established between Medisca and Deebio, is what gave us the confidence in choosing Medisca as our primary supplier of Thyroid Powder, USP,” said Gustavo Adolfo Porras, Head of Sales, North America at SUANFARMA. “We look forward to continuing to expand our strong relationship with Medisca.”
For Medisca, the mission is simple – to drive forward worldwide access to qualified products by developing strategic partnerships aligned to the same standards of quality, consistency, and affordability that define Medisca.
Medisca remains the leading supplier of Thyroid Powder, USP to compounding pharmacies. Available for purchase online here .
SUANFARMA will now streamline distribution to Medisca’s supply of Thyroid Powder, USP to other channels and markets.
About MEDISCA®
MEDISCA is a global leader in healthcare with well-established footings in pharmaceutical compounding and advancements in scientific labs, cosmetics, other healthcare industries. For 30+ years, MEDISCA has been serving pharmacies and allied healthcare institutions with cutting-edge offerings and passionate commitment, developing a worldwide network dedicated to personalized medicine. Through genuine relationships, worry-free experiences, convenient processes, and strategic global partnerships, MEDISCA provides top-quality and innovative products, industry-leading services, and world-class support systems. For more information visit www.medisca.com and follow us on Twitter at @medisca .
About SUANFARMA
SUANFARMA founded in 1993, is a B2B life science partner specialized in the development, production, and commercialization of ingredients for the pharmaceutical, veterinary and nutraceutical industries. Our facilities comply with the highest existing regulations in the pharmaceutical industry. With the support of a consolidated and strong commercial network with 12 local offices placed strategically around the world, SUANFARMA provides its services to more than 3.000 active customers in over 70 countries. For more information, visit www.suanfarma.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220526005571/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Wolters Kluwer enhances its Libra legal AI workspace in Italy by adding content specializations for One and integrating with Kleos11.6.2026 09:00:00 CEST | Press release
Libra by Wolters Kluwer integrates AI with authoritative, expert-generated content and operational workflows, supporting legal professionals across the entire workflow Wolters Kluwer Legal & Regulatory announced today new content and feature integrations in its legal AI workspace Libra by Wolters Kluwer for the Italian market. Customers will have access to additional expert-generated content in compliance, criminal law and tax law, and profit from the integration with Kleos, the cloud-based practice management solution for law firms. Designed to support the daily work of legal professionals, Libra by Wolters Kluwer combines advanced AI functionalities with trusted sources and authoritative, author-generated legal content. Within a single environment, it enables research, analysis and drafting activities based on reliable sources, while maintaining full control over results and quality. By integrating additional expert content from One, Wolters Kluwer’s leading legal research platform,
Pleo Announces New Agentic Capabilities, Changing the Face of Financial Management and Decision-Making11.6.2026 09:00:00 CEST | Press release
Pleo’s new agentic capabilities to let finance teams focus on strategic command, not admin These new agentic capabilities offer a clear path forward for finance leaders: especially when 63% say AI skills, training and confidence are severely lagging. Pleo, Europe's first and most trusted strategic finance platform, today announces a suite of AI agents that handle routine spend management autonomously, so finance leaders can focus on decisions rather than administrative tasks. Finance teams are under growing pressure: 45% of European companies say their current processes slow them down, and leaders describe approval workflows as so cumbersome they struggle to operate at the required speed. Meanwhile, 73% believe the future of finance teams and professionals depends on the comprehensive understanding and use of AI, yet 63% say AI skills, training and confidence are severely lagging. Pleo's agentic AI addresses this gap. Starting with beta testing in July, Pleo is moving toward a model wh
BearingPoint Danmark leverer 85% omsætningsvækst i 2025 og offentliggør års- og bæredygtighedsrapport11.6.2026 09:00:00 CEST | Pressemeddelelse
Stærk kundeefterspørgsel, et banebrydende AI projekt med Danske Bank og en betydelig medarbejdervækst skaber fremdrift på det danske marked og omsætter Strategy 2030 til konkrete resultater i Danmark. BearingPoint Danmark opnåede en omsætningsvækst på 85% i 2025, drevet af stærk efterspørgsel efter AI og rådgivning til den finansielle sektor, i forbindelse med offentliggørelsen af virksomhedens Årsrapport 2025, ”Future in focus” samt Bæredygtighedsrapport 2025, som markerer overgangen fra strategi til konkret eksekvering. Rapporterne viser, hvordan virksomheden skalerer anvendelsen af AI på tværs af organisationen, styrker sin globale leverancemodel og integrerer bæredygtighed i både strategi og kundeleverancer. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260611802927/da/ BearingPoint Danmark opnåede en omsætningsvækst på 85% i 2025, drevet af stærk efterspørgsel efter AI og rådgivning til den finansielle sektor, i forb
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions11.6.2026 08:01:00 CEST | Press release
- Data from pivotal studies of CASGEVY in children ages 5–11 with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrate transformative potential in younger patients, consistent with the durable benefits established in patients 12 years and older -- Data simultaneously published in the New England Journal of Medicine -- Regulatory review underway in the United States to expand the use of CASGEVY, and Vertex has recently completed submissions in the Kingdom of Saudi Arabia and United Kingdom - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, from pivotal studies in children ages 5–11, show that the efficacy and safety outcomes in this age group are consistent with the transformative profile established in adult and adolescent p
PUMA Brings NITRO™ to Football With the PUMA NITRO Lab in Los Angeles11.6.2026 08:00:00 CEST | Press release
Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and NITRO™'s arrival in football for the first time on a football boot. Previous editions of the NITRO™ Lab in Paris, Tokyo, and London explored the future of running performance and cemented NITRO™ as the defining technology in elite running with Fast-R3. Now, with the world’s attention turning to football, Los Angeles is where that journey takes its next step, introducing the same innovation DNA that reshaped the track to the pitch, when it matters most. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260610728823/en/ Global sports brand PUMA today opened the PUMA NITRO™ Lab in Los Angeles, the latest chapter of its innovation platform, and company’s most significant yet, marking the global reveal of the Ultra Nitro 7 and N
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
